Tina Marriott - Feb 1, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: President and COO
Signature: /s/ Nathan Hatfield, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Feb 1, 2023
Transactions value $: -$26,445
Form type: 4
Date filed: 2/3/2023, 04:13 PM
Previous filing: Jan 27, 2023
Next filing: Feb 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+217K	+105.5%	$0.00	423K	Feb 1, 2023	Direct	F1, F2
transaction	RXRX	Class A Common Stock	Award	$0	+9.73K	+2.3%	$0.00	433K	Feb 1, 2023	Direct	F3
transaction	RXRX	Class A Common Stock	Tax liability	-$26.4K	-3.09K	-0.72%	$8.55	429K	Feb 1, 2023	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+434K		$0.00	434K	Feb 1, 2023	Class A Common Stock	434K	$8.55	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						554K	Feb 1, 2023	Class A Common Stock	0	$1.06	Direct	F6
holding	RXRX	Stock Option (Right to Buy)						159K	Feb 1, 2023	Class A Common Stock	0	$11.40	Direct	F7
holding	RXRX	Stock Option (Right to Buy)						4.78K	Feb 1, 2023	Class A Common Stock	0	$11.40	Direct
holding	RXRX	Stock Option (Right to Buy)						150K	Feb 1, 2023	Class A Common Stock	0	$2.48	Direct	F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter.
F2	Includes 2093 shares acquired under the Recursion stock purchase plan on May 20, 2022.
F3	This RSU vested immediately upon the grant date.
F4	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F5	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6	Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F7	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F8	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.